Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (October 2019)
20 slides from Imagion Biosystems's investor presentation, Oct 28, 2019
Slide 1: MagSense Technology: Early Detection of Cancer Through Targeted Imaging
For personal use only ® B I O S Y S T E M S MagSense™ Technology Early Detection of Cancer Through Targeted Imaging ASX:IBX www.imagionbiosystems.com
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire
Slide 3: Imagion Biosystems At-a-Glance
I M A G I O N B I O S Y S T E M S AT- A - G L A N C E New medical imaging technologies for the early detection of cancer For personal use only Imagion Biosystems • Innovative medical imaging using magnetic nanoparticles to identify and ASX:IBX stage cancer early Australian Medical Device Company dev
Slide 4: A Growing Global Health Problem
A G R O W I N G G L O B A L H E A LT H P R O B L E M 1 in 3 people are affected by cancer For personal use only CANCER DIAGNOSTICS - $100B MARKET $30,000 $100B spent annually to $26,044 $25,000 $20,000 $20,136 diagnose or detect Millions $15,000 $15,541 cancer, yet cancer $7,246 $8,850 $9,632 contin
Slide 5: Clear Unmet Medical Need
CLEAR UNMET MEDICAL NEED 50 years since last new imaging technology was introduced For personal use only COMPUTED POSITRON X-RAY MAGNETIC EMISSION ULTRASOUND TOMOGRAPHY (MAMMOGRAPHY) 1956 (CT) RESONANCE (MRI) TOMOGRAPHY Current Imaging Technologies: 1895 (1913) 1972 1971 (PET) 1973 Relatively inexpe
Slide 6: Medical Imaging Breakthrough
MEDICAL IMAGING BREAKTHROUGH MagSense™ Technology will transform cancer diagnosis For personal use only • Non-invasive – a safe and non-surgical solution to detect cancer • No radioactivity - uses bio-safe magnetic nanoparticles to “tag” cancer cells • Platform technology – can be used for many canc
Slide 7: A Chance to Improve Outcomes
A CHANCE TO IMPROVE OUTCOMES Better sensitivity could mean earlier detection MagSense™ technology is expected to have sensitivity comparable to PET without use of radioactivity, making it For personal use only better for routine use in early detection and resulting in more successful treatments and
Slide 8: Broad Commercial Applicability
BROAD COMMERCIAL APPLICABILITY Can be used for many types of cancer and at multiple stages of diagnosis For personal use only MAGSENSE NANOPARTICLES • Are bio-functionalized to ensure high specificity for Multiple Clinical Targets targeting different types of cancers, or other diseases. • Can be use
Slide 9: Transformative for Medical Imaging
T R A N S F O R M AT I V E F O R M E D I C A L I M A G I N G Designated by FDA as a “Breakthrough Device” For personal use only The MagSense™ HER2 Metastatic Breast Cancer Test • Works within current standard cancer diagnosis and staging protocols. • Replaces current non-functional imaging such as M
Slide 10: Investment Rationale
I N V E S T M E N T R AT I O N A L E Strategic plan provides path to future products & shareholder value For personal use only STAGING TUMOR MRI TREATMENT DOCTORS DETECTION & BREAST CANCER DETECTION CONTRAST MONITORING OFFICE THERAPY Reduce unnecessary Breast, prostate, lung Safer alternative to Mon
Slide 11: How It Works
HOW IT WORKS Bio-safe magnetic nanoparticles are attracted to the tumor and detected For personal use only • Nanoparticles, specific for the cancer, bind to tumor cells. • Nanoparticles demagnetize or “relax” after exposure to a low magnetic field. • Nanoparticles attached to cancer cells “relax” mo
Slide 12: Pre-Clinical Research
PRE-CLINICAL RESEARCH Product performance verified in pre-clinical models For personal use only SPECIFICITY • In vitro cell based studies confirm specificity for HER2 expressing breast cancer cells. • Animal studies confirm in vivo selectivity for HER2 expressing breast cancer tumours. SENSITIVITY •
Slide 13: Improving MRI Diagnostic Utility
IMPROVING MRI DIAGNOSTIC UTILITY Additional commercial opportunity as an MRI contrast agent For personal use only • MagSense™ iron oxide nanoparticles generate T2* MRI contrast even at low concentrations. • Targeted nanoparticles would change MRI from identifying a region of interest to imaging for
Slide 14: Strong R&D Pipeline
STRONG R&D PIPELINE Product Applications Under Development For personal use only Research Pre-Clinical Clinical Design In Vitro Animal Models Tox/Safety Early Feasibility Pivotal Metastatic HER2 Breast Cancer MRI Contrast • Parallel development for use with installed base of Agent MRI scanners; may
Slide 15: Compelling Business Model
COMPELLING BUSINESS MODEL Proprietary consumable drives growth & profitability For personal use only PRINTER / INK ONE INSTRUMENT MANY TESTS REVENUE MODEL 35% capacity utilization HER2 Breast Ovarian Cancer A$2.2 million annual Cancer revenue per instrument Prostate Lung Cancer Cancer Revenue throug
Slide 16: Milestones and Valuation Drivers
M I L E S TO N E S A N D VA L U AT I O N D R I V E R S Indicative development timeline and key inflection points in first indication* For personal use only • On track for first-in-human study in FY20 – study duration expected to be 3-6 months. • First human data key validation point, paves way for d
Slide 17: Experienced Team
EXPERIENCED TEAM Commercially focused team with deep industry & clinical experience For personal use only World class scientific collaborations & partnerships: ROBERT PROULX MICHAEL HARSH DAVID LUDVIGSON BRONWYN LE GRICE CHAIRMAN & CEO NON EXEC DIRECTOR NON EXEC DIRECTOR NON EXEC DIRECTOR • Operatio
Slide 18: Capital Structure
C A P I TA L S T R U C T U R E No debt, one class of common stock For personal use only Ordinary shares on issue 327.37M* Share price (24 Oct 2019) 0.040 Price ( AUD) Average daily volume 281K $0.056 Market capitalization 13.09M (24 Oct 2019) $0.046 Net cash (30 June 2019) $1.1M $0.036 (+ further $2
Slide 19: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only LARGE OPPORTUNITY UNIQUE TECHNOLOGY $100B cancer diagnostic market New form of medical imaging Growing 7% annually Molecularly specific & non-invasive Medical imaging commands largest share More sensitive than current methods Huge medical need for early di
Slide 20: Imagion Biosystems
For personal use only ® B I O S Y S T E M S IMAGION BIOSYSTEMS www.imagionbiosystems.com
Imagion Biosystems — Investor Presentation (October 2019) on 6ix